Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.50 |
| ▸ | CA9 | Q16790 | 9/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910581 | 0.97 | GLA (0.53) | GLAGAACA2CA9CISD1 | |
| Cyclohexane SCHEMBL8339037 | 0.92 | GLA (0.47) | GLAGAACA2CA9CISD1 | |
| Ammonia Solution, Strong SCHEMBL7929452 | 0.88 | CA2 (0.59) | GLAGAACA2CA9CA1 | |
| SCHEMBL232089 | 0.87 | CISD1 (0.58) | GLAGAACA2CA9CISD1 | |
| Urea SCHEMBL27973636 | 0.87 | CA2 (0.50) | GLAGAACA2CA9CISD1 | |
| Ammonia Solution, Strong SCHEMBL1115426 | 0.87 | CA1 (0.56) | GLAGAACA2CA9CISD1 | |
| SCHEMBL14015383 | 0.85 | CA2 (0.49) | GLAGAACA2CA9CISD1 | |
| SCHEMBL14015361 | 0.85 | CA1 (0.61) | GLAGAACA2CA9CA1 | |
| SCHEMBL14015363 | 0.85 | CA2 (0.61) | GLAGAACA2CA9CISD1 | |
| SCHEMBL11245853 | 0.85 | CA2 (0.61) | GLAGAACA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0450198-B1 | Developer liquid for high contrast development | AGFA GEVAERT NV (BE) | 1995-07-26 | — | — | EP | claimed |
| US-5141843-A | Phenyl tetrazole anti-fogging agent | AGFA-GEVAERT N. V. (BE) | 1992-08-25 | — | — | US | claimed |
| EP-0450198-A1 | Developer liquid for high contrast development | AGFA-GEVAERT N.V. (BE) | 1991-10-09 | — | — | EP | claimed |
| US-20250025399-A1 | AGENT FOR OXIDATIVELY DYEING KERATIN FIBERS, CONTAINING AT LEAST ONE OXIDATION DYE PRECURSOR OF THE DEVELOPER TYPE AND ISATIN | HENKEL AG & CO. KGAA (DE) | 2025-01-23 | — | — | US | disclosed |
| US-20250017838-A1 | Agent for Oxidatively Dyeing Keratin Fibers | HENKEL AG & CO. KGAA (DE) | 2025-01-16 | — | — | US | disclosed |
| EP-2657151-B1 | VALVE ASSEMBLY AND AEROSOL CONTAINER EQUIPPED WITH SAME, AND AEROSOL PRODUCT AND PROCESS FOR PRODUCTION THEREOF | DAIZO CORP (JP) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019142829-A1 | PROTEOGLYCAN, AND METHOD FOR PRODUCING HEALTH FOOD, HEALTH BEVERAGE, PHARMACEUTICAL COMPOSITION, OR COSMETIC COMPOSITION INCLUDING SAME | 一丸ファルコス株式会社 | 2019-07-25 | — | — | WO | disclosed |
| US-9926130-B2 | Valve assembly and aerosol container equipped with the same, and aerosol product and process for production thereof | DAIZO CORPORATION (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20160376089-A1 | VALVE ASSEMBLY AND AEROSOL CONTAINER EQUIPPED WITH THE SAME, AND AEROSOL PRODUCT AND PROCESS FOR PRODUCTION THEREOF | DAIZO CORP (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9475636-B2 | Valve assembly and aerosol container equipped with the same, and aerosol product and process for production thereof | DAIZO CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9358190-B2 | Dyeing composition | AMOREPACIFIC CORPORATION (KR) | 2016-06-07 | — | — | US | disclosed |
| EP-0670053-A1 | SOLID ANTIFOGGANT AGENT AND SOLID SINGLE PART HIGH CONTRAST RAPID ACCESS DEVELOPER | SUN CHEMICAL CORPORATION (US) | 1995-09-06 | — | — | EP | disclosed |
| EP-0450198-B1 | Developer liquid for high contrast development | AGFA GEVAERT NV (BE) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994011783-A1 | SOLID ANTIFOGGANT AGENT AND SOLID SINGLE PART HIGH CONTRAST RAPID ACCESS DEVELOPER | SUN CHEMICAL CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| US-5272045-A | Water soluble antifoggant for powder developer solutions | SUN CHEMICAL CORPORATION (US) | 1993-12-21 | — | — | US | disclosed |
| US-5141843-A | Phenyl tetrazole anti-fogging agent | AGFA-GEVAERT N. V. (BE) | 1992-08-25 | — | — | US | disclosed |
| EP-0495253-A1 | Method for the photographic production of silver images | AGFA-GEVAERT N.V. (BE) | 1992-07-22 | — | — | EP | disclosed |
| EP-0450198-A1 | Developer liquid for high contrast development | AGFA-GEVAERT N.V. (BE) | 1991-10-09 | — | — | EP | disclosed |
| US-4756990-A | Developer contains hydroquinone compound, auxilliary developer, free sulfite ions, antifogging agent, alkylene oxide containing polymer, inorganic alkali | AGFA-GEVAERT N.V. (BE) | 1988-07-12 | — | — | US | disclosed |
| EP-0030747-A1 | 2-Equivalent yellow-forming colour couplers, their use in the production of photographic colour images, and photographic elements containing such couplers | AGFA-GEVAERT N.V. (BE) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025399-A1 | AGENT FOR OXIDATIVELY DYEING KERATIN FIBERS, CONTAINING AT LEAST ONE OXIDATION DYE PRECURSOR OF THE DEVELOPER TYPE AND ISATIN | OAT, KRT18, ARG2 | GLA 1094/4885GAA 4350/4885CA2 1573/4885 |
| US-20250017838-A1 | Agent for Oxidatively Dyeing Keratin Fibers | KRT18, SQOR, ADH4 | GLA 892/4885GAA 4565/4885CA2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.